First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and …
Y Song, S Lin, J Chen, J Dang - BMC cancer, 2023 - Springer
Background It remains uncertain whether first-line treatment with upfront brain radiotherapy
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
Modern stereotactic radiotherapy for brain metastases from lung cancer: current trends and future perspectives based on integrated translational approaches
M Levis, A Gastino, G De Giorgi, C Mantovani… - Cancers, 2023 - mdpi.com
Simple Summary In the current era of precision medicine, the management of patients with
brain metastases (BMs) is rapidly evolving. The technical evolution of radiotherapy, now …
brain metastases (BMs) is rapidly evolving. The technical evolution of radiotherapy, now …
In-silico identification of small molecule benzofuran-1, 2, 3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore …
Lung cancer is one of the most common and deadly types of cancer worldwide, and the
epidermal growth factor receptor (EGFR) has emerged as a promising therapeutic target for …
epidermal growth factor receptor (EGFR) has emerged as a promising therapeutic target for …
Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and …
Purpose To examine the differential effects of SRS and TKI on EGFR-mutated NSCLC
patients with brain metastases (BMs) and outcomes following continuation of the same TKI …
patients with brain metastases (BMs) and outcomes following continuation of the same TKI …
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 …
Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
Different tyrosine kinase inhibitors used in treating EGFR-mutant pulmonary adenocarcinoma with brain metastasis and intracranial intervention have no impact on …
Simple Summary Brain metastasis is a factor of a poor prognosis in patients with non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in …
Y Uehara, Y Takeyasu, T Yoshida, A Tateishi… - ESMO Real World Data …, 2024 - Elsevier
Background Osimertinib has been the standard of care in epidermal growth factor receptor
(EGFR)-mutant non-small-cell lung cancer (NSCLC). We evaluated outcomes between …
(EGFR)-mutant non-small-cell lung cancer (NSCLC). We evaluated outcomes between …
Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review
J Xu, Z Wang - Frontiers in Oncology, 2023 - frontiersin.org
Targeted drug therapy plays an important role in the clinical application of non-small cell
lung cancer, especially adenocarcinoma. However, for patients with advanced disease, drug …
lung cancer, especially adenocarcinoma. However, for patients with advanced disease, drug …
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010-2019 …
Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery
(SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers …
(SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers …